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15 Abstract
16 In 2006, cells heterologously expressing the “orphan” receptor GPR17
17 were shown to acquire responses to both uracil nucleotides and cysteinyl-
18 leukotrienes, two families of signaling molecules accumulating in brain or
19 heart as a result of hypoxic/traumatic injuries. In subsequent years, evi-
20 dence of GPR17 key role in oligodendrogenesis and myelination has
21 highlighted it as a “model receptor” for new therapies in demyelinating
22 and neurodegenerative diseases. The apparently contrasting evidence in
23 the literature about the role of GPR17 in promoting or inhibiting
24 myelination can be due to its transient expression in the intermediate
25 stages of differentiation, exerting a pro-differentiating function in early
26 oligodendrocyte precursor cells (OPCs), and an inhibitory role in late
27 stage maturing cells. Meanwhile, several papers extended the initial data
28 on GPR17 pharmacology, highlighting a “promiscuous” behavior of this
29 receptor; indeed, GPR17 is able to respond to other emergency signals like
30 oxysterols or the pro-inflammatory cytokine SDF-1, underlying GPR17
31 ability to adapt its responses to changes of the surrounding extracellular
32 milieu, including damage conditions. Here, we analyze the available
33 literature on GPR17, in an attempt to summarize its emerging biological
34 roles and pharmacological properties.
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160 Introduction: The History
61 of GPR17
62 In 2006, a paper was published where it was
63 demonstrated that cells heterologously
64 expressing the “orphan” receptor GPR17 (i.e., a
65 molecularly identified, 339 amino acid-long
66 Gi-protein-coupled receptor that still lacked a
67 defined ligand) acquired responses to both uracil
68 nucleotides (such as UDP, UDP-glucose,
69 UDP-galactose) and cysteinyl-leukotrienes
70 (cysLTs, like LTC4 and LTD4) (Ciana et al.
71 2006), two chemically unrelated families of sig-
72 naling molecules that are known to massively
73 accumulate in organs like the brain or the heart
74 as a result of hypoxic/traumatic injuries. Uracil
75 nucleotides and cysLTs were already known to
76 exert multiple biological effects via the
77activation of separate G-protein-coupled
78receptors (GPCRs): the eight recognized P2Y
79receptor subtypes (the P2Y1,2,4,6,11,12,13,14
80receptors, (Abbracchio et al. 2006) and the two
81CysLT1 and CysLT2 receptors. Interestingly, the
82GPR17 sequence had been originally described
83as the result of a cloning strategy based on the
84use of RT-PCR degenerate oligonucleotide
85primers designed on the sequences of the P2Y1
86and P2Y2 receptors, with the final aim of
87identifying new members of this receptor family
88(Blasius et al. 1998). GPR17 was later found to
89be at an intermediate structural and phylogenetic
90position between already known P2Y and CysLT
91receptors, and GPR99, recently proposed as the
92third CysLT receptor (also known as
932-oxoglutarate receptor 1, OXGR1) (Kanaoka
94et al. 2013) (Fig. 1), in the so called “purine
95receptor cluster” of class A GPCRs (Fredriksson
96et al. 2003). GPR17 also emerged as represented
97the closest receptor to a common ancestor that,
98during evolution, could have generated both P2Y
99and CysLT receptors (Ciana et al. 2006;
100Parravicini et al. 2008; Parravicini et al. 2010).
101To further highlight GPR17 structural similarity
102to the other members of the P2Y family, a partial
103sequence of the rat receptor was initially
104identified from rat striatum by employing oligo-
105nucleotide primers specifically designed on the
106sequence of human P2Y11 (Lecca and
107Abbracchio 2008). Of note, a human GPR17
108long splice variant encoding a receptor with a
10928-amino acid longer NH2 terminal (for a total
110of 367 amino acids instead of 339) had been also
111identified in very early studies aimed at discov-
112ering new members of the chemokine receptor
113family (in this respect, see also Sect. 2.1)
114(Blasius et al. 1998). Genomic analysis revealed
115a three-exon structure of the hGPR17 gene, with
116two putative open reading frames. While the
117“short isoform” derives from splicing of the
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118 second exon, the “long one” contains all three
119 exons of the hGPR17 gene, leading to a transcript
120 which is 1104 bp in length (Blasius et al. 1998;
121 Pugliese et al. 2009). Interestingly, quantitative
122 gene expression studies revealed that GPR17
123 short isoform is expressed more abundantly in
124 the brain than the long one (a tenfold increase),
125 whereas the opposite was observed in heart and
126 kidney. Pharmacological profile of the long iso-
127 form also showed that some differences exist
128 between the two GPR17 receptor isoforms
129 (Pugliese et al. 2009; Benned-Jensen and
130 Rosenkilde 2010).
131In 2006, there were already papers reporting
132functional interactions between “classical” P2Y
133and CysLT receptors. For example, under some
134conditions, the CysLT1 receptor antagonist
135montelukast effectively antagonized the
136responses evoked by purinergic P2Y receptors
137(Capra et al. 2005; Mamedova et al. 2005). Con-
138versely, the P2Y12 receptor had been reported to
139be also activated by LTE4 (Paruchuri et al. 2009),
140suggesting the existence of some kind of ligand/
141receptor promiscuity between the P2Y and
142CysLT receptor families. On this basis, the iden-
143tification of GPR17 as the first dual member of
144the “purine receptor cluster” able to respond to
Fig. 1 Phylogenetic tree illustrating the relationship
of GPR17 to selected structurally related class-A
GPCRs. The evolutionary relationship analysis is based
on a multiple sequence alignment performed on homolo-
gous GPCR sequences using TM-Coffee, a module of the
T-Coffee package optimized for transmembrane proteins
(Chang et al. 2012). Receptors belonging to the same
family are clustered according to the following color
code: grey for purinergic receptors (P2Y), orange for
cysteinyl-leukotriene receptors (CysLT), light green for
chemokine receptors (CXCRn, CCRn, XCRn), emerald
green for Epstein-Barr virus-induced G-protein coupled
receptor 2 (EBI2), sky blue for 2-Oxoglutarate receptor
1 (OXGR1/GPR99), apple green for GPR17
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145 both purinergic and cysLT ligands (Ciana et al.
146 2006) represented the demonstration of a further
147 level of interaction between these two chemi-
148 cally unrelated, but functionally interconnected,
149 systems. Later studies extended the response pro-
150 file of this receptor to other classes of endoge-
151 nous “emergency” molecules connected to
152 oxidative stress, neuroinflammation and
153 neurodegeneration, i.e., oxysterols and chemo-
154 kine stromal derived factor-1 (SDF-1)
155 (Parravicini et al. 2016), further highlighting the
156 promiscuous behaviour of GPR17. Of note, a
157 phylogenetic analysis among structurally related
158 class-A GPCRs (Parravicini et al. 2008, 2010,
159 2016; Sensi et al. 2014), suggest that, besides
160 P2Y and CysLT receptors, GPR17 holds a tight
161 evolutionary relationship also with chemokine
162 receptors and Epstein-Barr virus-induced
163 G-protein coupled receptor 2 (EBI2) (Fig. 1).
164 The possibility that GPR17 can be activated by
165 diverse family of ligands underlines the rele-
166 vance of a new transversal signaling mechanism
167 that synchronizes all these emergency molecules
168 and their receptors under specific neurodegener-
169 ative conditions. Such a high promiscuity in
170 receptor behaviour is often found in receptors
171 involved in immunological responses and may,
172 at least in part, depend on GPR17 ability to form
173 dimers with other related receptors, thus widen-
174 ing the array of pharmacological responses (see
175 also Sect. 2.2.1).
176 In subsequent years, new data have revealed a
177 key role for GPR17 in oligodendrogenesis and
178 myelination (Lecca et al. 2008; Chen et al. 2009).
179 However, while some authors have provided evi-
180 dence for a stimulatory role of GPR17 in the
181 specification and maturation of oligodendrocyte
182 precursor cells (OPCs), some others have pro-
183 posed an inhibitory role. Here, we aim at
184 analyzing all the available literature on GPR17
185 in an attempt to provide an overview of the
186 different biological and pharmacological data
187 emerged from all these papers.
2 188GPR17 Characterization
2.1 189Receptor Structure, Amino Acid
190Homology with Phylogenetically
191Related GPCRs and Binding Sites
192GPR17 displays the typical 7-transmembrane
193(TM) domain topology of GPCRs, with an
194amino acid identity with the known P2Y and
195CysLT receptors between 21 and 48%
196(Abbracchio et al. 2006; Lecca and Abbracchio
1972008). All these receptors show partial or com-
198plete conservation of a H-X-X-R/K amino acid
199motif in TM6 (and also of a K-E-X-X-L motif in
200TM7, in the case of P2Y12, P2Y13, P2Y14) that
201are important for ligand recognition and have
202been proposed to represent specific molecular
203signatures for these receptors (Lecca and
204Abbracchio 2008) (see also below). Homology
205Modelling (HM) studies combined with other in
206silico tools have been performed to raise hypoth-
207esis on the molecular interaction between GPR17
208and its putative endogenous ligands (Parravicini
209et al. 2008, 2010; Calleri et al. 2010), as well as
210to identify new potential ligands (Eberini et al.
2112011) (see also Sect. 2.2.2). In these studies, in
212silico receptor modeling was performed using
213different templates, according to the progressive
214availability of new high-resolution GPCR
215structures. Starting from bovine rhodopsin, that,
216since 2000, has represented for many years the
217only atomistic scaffold for the structural investi-
218gation of GPCRs, the recent explosion in the
219resolution of GPCR crystal structures has given
220access to detailed structural information previ-
221ously unavailable, allowing the construction of
222more and more accurate GPR17 models (Fig. 2).
223For example, in 2010, crystallization of
224human CXCR4 (Wu et al. 2010) provided a sig-
225nificant improvement in the accuracy of GPR17
226modelling because this structure enabled to reli-
227ably describe the extracellular regions of the
228receptor, especially extracellular loop 2 (ECL2)
229and the disulphide bridge linking the N-terminal
230to ECL3, known to be crucial in ligand molecular
231recognition (Wheatley et al. 2012), but for which
232none of the earlier templates was suitable. More
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233 recently, modelling of GPR17 has been further
234 improved thanks to the atomic resolution of the
235 structures of two members of the P2Y receptor
236 family: the human P2Y12 (Zhang et al. 2014) and
237 P2Y1 (Zhang et al. 2015).
238 Globally, all the in silico results on the short
239 isoform of GPR17 suggest that its nucleotide
240 binding pocket is similar to that described for
241 the other P2Y receptors (including the TM6
242 HXXR/K motif designated to accommodate the
243 phosphate moieties of nucleotide ligands
244 (Parravicini et al. 2008; Jiang et al. 1997), and
245 that this site is also shared by other small
246 molecules identified as GPR17 ligands, including
247 oxysterols and new synthetic compounds (Sensi
248 et al. 2014; Eberini et al. 2011). According to
249 these studies, also the nucleotide-derivative
250 antagonist cangrelor binds to the same binding
251 pocket, behaving as a competitive antagonist for
252 orthosteric ligands.
253 In both P2Y and CysLT1 and CysLT2
254 receptors, ligand binding is critically dependent
255 on the basic Arginine residue belonging to the
256conserved TM6 motif (Parravicini et al. 2010;
257Temporini et al. 2009). Computational studies
258suggested that this also holds true for Arg255 of
259GPR17 (Parravicini et al. 2008). To assess the
260actual role of this residue in receptor binding, this
261basic amino acid was mutated to isoleucine, and
262an in silico mutant GPR17 receptor (R255I) was
263generated. Using steered molecular dynamics
264simulations (SMD), forced unbinding of the
265endogenous ligand UDP from both wild type
266(WT) and R255I receptor models of GPR17
267was modeled in silico. The energy required to
268unbind UDP from the nucleotide binding pocket
269of GPR17 was higher for the WT than for the
270mutated R255I receptor, and the exit of the
271ligand from its intracellular cavities occurred
272earlier in the R255I model compared to the WT
273receptor. Generation and expression of the
274mutated receptor in 1321N1 cells confirmed
275also in vitro that the mutation was not silent
276(Calleri et al. 2010).
277Besides the orthosteric binding site, in silico
278studies suggested that GPR17 also possesses an
279“accessory” binding site in a region formed by
280extracellular loops ECL2, ECL3 and the N- ter-
281minal, which also faces the extracellular space.
282This external accessory binding site could guide
283small agonist ligands to the deeper principal
284binding site in a multistep mechanism of activa-
285tion. Thanks to further in silico investigations,
286that showed the possibility of GPR17 to be
287stimulated also by a large peptide ligand such
288as SDF-1, the extracellular recognition site has
289been extensively characterized and GPR17 rec-
290ognition mechanism has been compared to those
291of some peptide receptors (Parravicini et al.
2922016), in which a two-step model of receptor
293activation, passing through both an extracellular
294and a TM binding site, has been proposed
295(Rajagopalan and Rajarathnam 2004).
296Due to the intrinsic inaccuracy of the standard
297template-based HM techniques in predicting
298conformations of highly flexible and unaligned
299loop sequences in absence of adequate templates,
300no modeling studies are yet available for the long
301isoform of GPR17. Nevertheless, we can specu-
302late that the N-terminal may influence the bind-
303ing affinity of nucleotide agonists via a different
Fig. 2 Three-dimensional homology model of the
human GPR17. Topological domains are represented as
ribbon and coloured according to their secondary struc-
ture: magenta for alpha-helices; yellow for beta-sheets;
white for loops and grey for turns
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304 conformation of the external accessory binding
305 site, resulting in a slightly different pharmaco-
306 logical profile of the long isoform with respect to
307 the short one (Pugliese et al. 2009).
2.2308 Pharmacology and Signaling
309 Pathways
310 2.2.1
311
2 Putative Endogenous Ligands
3 and Transduction Systems
314 In the initial studies, only GPR17 short isoform
315 has been characterized, and both the human, rat
316 (Ciana et al. 2006) and the previously unidenti-
317 fied mouse GPR17 receptors (Lecca and Ceruti
318 2008) were shown to respond to UDP,
319 UDP-glucose, UDP-galactose and LTC4 and
320 LTD4, with comparable profiles that were highly
321 conserved across species (the chemical structures
322 of UDP-glucose and LTD4 are reported in
323 Fig. 3). Interestingly, the concentration ranges
324 at which uracil nucleotides and cysLTs activated
325 GPR17 (i.e., μM and nM ranges, respectively)
326 were fully consistent with those necessary for
327 these endogenous ligands to activate their
328 already known cognate P2Y and CysLT
329 receptors (Abbracchio et al. 2006; Brink et al.
330 2003). Very similar agonist responses were
331 detected in a number of different cell lines
332 (1321N1, CHO, COS-7, HEK-293 cells). The
333 1321N1 cells was the most appropriate cells to
334 test GPR17 responses, since they are one of the
335 few cell lines that do not endogenously express
336 any functional purinergic or CysLT receptors.
337 Responses were highly specific, since no
338 response was ever found in cells transfected
339 with the empty vector. The antagonist response
340 profile of GPR17 was also rather peculiar. Acti-
341 vation by uracil nucleotides was reversed by
342 some typical purinergic antagonists like the
343 P2Y1 antagonist MRS2179 or the P2Y12 antago-
344 nist cangrelor (Fig. 3). Conversely, responses to
345 cysLTs were inhibited by typical CysLT receptor
346 antagonists like the already marketed drug
347 montelukast (Fig. 3) and pranlukast (Ciana
348 et al. 2006).
349 GPR17 responses were demonstrated by using
350 [35S]GTPγS binding, a typical functional assay
351for agonists acting at Gi coupled receptors
352(Kotani et al. 2001; Marteau et al. 2003;
353Fumagalli et al. 2004). Under some
354circumstances, activation of GPR17 could also
355increase intracellular calcium levels via a phos-
356pholipase C mediated pathway; however, this
357effect occurred only in about 30% of 1321N1
358transfected cells, suggesting preferential cou-
359pling to the adenylyl cyclase pathway (Ciana
360et al. 2006). In subsequent studies, GPR17 pecu-
361liar profile was confirmed in many other distinct
362assays independently performed in different
363laboratories. Concentration-dependent inhibition
364of forskolin-stimulated adenylyl cyclase was also
365shown in oligodendendrocyte precursor cells
366(OPCs), the cell type natively expressing
367GPR17 at highest levels (Fumagalli et al.
3682011a) (Table 1). Inhibition of cAMP was fully
369counteracted by the same antagonists utilized in
370the [35S]GTPγS binding. In 2009, another paper
371appeared where, in GPR17 expressing 1321N1
372cells, enhancement of an outward rectifying K+
373current was shown upon addition of either uracil
374nucleotides or cysLTs (Pugliese et al. 2009).
375These effects were blocked by MRS2179,
376cangrelor and montelukast. A few years later,
377these same authors showed that similar delayed
378rectifier K+ currents were stimulated in a concen-
379tration dependent manner by GPR17 ligands in a
380subpopulation of OPCs and
381pre-oligodendrocytes, but not in terminally
382mature cells, fully in line with the transient
383expression of GPR17 during OPC specification
384(in this respect, see also Sect. 3.1.1) (Coppi et al.
3852013). This effect was blocked by MRS2179 and
386cangrelor and sensitive to the K+ channel blocker
387tetraethyl-ammonium. Importantly, the latter
388also inhibited oligodendrocyte maturation, to
389support previous literature data on the impor-
390tance of these currents in OPC differentiation.
391Fewer studies are available on hGPR17 long
392isoform. In the electrophysiological study
393already mentioned above, no significant
394differences between the short and long isoforms
395were detected (Pugliese et al. 2009). In 2010,
396Benned-Jensen and Rosenkilde independently
397confirmed the ability of heterologously
398expressed GPR17 to respond to uracil
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399 nucleotides in a cAMP response element binding
400 (CREB) trans-reporter luciferase assay in
401 HEK293 cells (Benned-Jensen and Rosenkilde
402 2010). Both UDP, UDP-glucose and
403UDP-galactose activated GPR17 short isoform
404with EC50 values exactly in the same μM range
405that had been previously reported in both the [35
406S]GTPγS binding (Ciana et al. 2006; Lecca et al.
Fig. 3 Chemical structures of endogenous and syn-
thetic compounds reported to bind GPR17. CAS Reg-
istry number of synthetic ligands are the following:
MDL29 AU1,951 #130798–51-5; ASN-1: #483283–39-2. For
SDF-1, a representative X-ray structure deposited in the
Protein Data Bank is reported (Pdb code: 1QG7)
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407 2008) and in frontal affinity chromatography-
408 mass spectrometry (FAC-MS) studies (Calleri
409 et al. 2010; Temporini et al. 2009). Much lower
410 potencies to uracil nucleotides were observed for
411 the long receptor isoform, with a 50–170 fold
412 increase in EC50 (Benned-Jensen and Rosenkilde
413 2010). Moreover, no responses to cysLTs were
414 detected either on the short or long isoform, nor
415 were cysLTs able to induce GPR17 removal
416 from the membrane and internalization. This is
417 in contrast with subsequent studies on cells
418 natively expressing the receptor (Fratangeli
419 et al. 2013) (see below). This may depend on
420 differences in the conformation/ability of the
421 recombinant receptor to respond to agonists com-
422 pared to the native one, as well as on the fact that,
423 in heterologously expressing systems, constitu-
424 tive activity of transfected receptors may
425significantly alter ligand behavior (Kenakin
4262001; Im 2013) (see also Conclusions). In this
427respect, Benned-Jensen and Rosenkilde indeed
428reported a notable constitutive activation of
429recombinant GPR17 resulting in potent inhibi-
430tion of forskolin stimulated adenylyl cyclase in
431the absence of any endogenous ligand (Benned-
432Jensen and Rosenkilde 2010).
433At the same time, another paper suggested
434GPR17 as a negative regulator of the CysLT1
435receptor (Maekawa et al. 2009). This effect was
436proposed to depend on the formation of a
437CysLT1-GPR17 heteromer, as suggested by
438co-immunoprecipitation studies in CHO cells.
439The interaction between GPR17 and CysLT1
440was further confirmed in primary human mono-
441cyte cells and in a rodent knock out GPR17
442model, thus extending to GPR17 the previously
t:1 Table 1 GPR17 signaling in native systems and relevant pharmacology
Tested
ligand Type of cells Signaling EC50/IC50 values Referencet:2
UDP-
glucose
Rat primary
OPCs
Inhibition of cAMP production IC50:
424.7  125 nM
Fumagalli et al.
(2011a)t:3
Rat primary
OPCs
Outward K+ currents EC50: 4.6 μM Coppi et al. (2013)t:4
Rat primary
OPCs
Association to GRK5 N.A. Daniele et al. (2014)t:5
Rat primary
OPCs
β-arrestin dependent ERK1/
2 activation
N.A. Daniele et al. (2014)t:6
Oli-neu cells Clathrin-mediated endocytosis N.A. Fratangeli et al.
(2013)t:7
PC12 cells ERK1/2 and p38 phosphorylation N.A. Daniele et al. (2010)t:8
UDP
LTD4
Rat primary
OPCs
Inhibition of cAMP production IC50:
1.29  0.07 μM
(Fumagalli et al.
2011a)t:9
Rat primary
OPCs
Inhibition of cAMP production IC50:
2.85  0.89 nM
Fumagalli et al.
(2011a)t:10
Rat primary
OPCs
Association to GRK2 N.A. Daniele et al. (2014)t:11
Rat primary
OPCs
CREB activation N.A. Daniele et al. (2014)t:12
PC12 cells ERK1/2 and p38 phosphorylation N.A. Daniele et al. (2010)t:13
Oli-neu cells Clathrin-mediated endocytosis N.A. Fratangeli et al.
(2013)t:14
LTE4 Rat primary
OPCs
Inhibition of cAMP production IC50: 51.8 6.6 pM Fumagalli et al.
(2011a)t:15
MDL29,951 Rat primary
OPCs
Inhibition of cAMP production N.A. Hennen et al. (2013)t:16
Rat primary
OPCs
Ca2+i increase N.A. Hennen et al. (2013)t:17
t:18 N.A.: Not available
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443 reported interaction and promiscuity between
444 different members of the “purine receptor clus-
445 ter”. These data indicate that, besides working on
446 its own, GPR17 may also modify the function of
447 other related receptors by the formation of
448 heteromers.
449 In 2010, the first paper describing the
450 characteristics of GPR17 in a native system (rat
451 pheocromocytoma PC12 cells) was published
452 (Daniele et al. 2010) (Table 1). GPR17 was not
453 expressed in undifferentiated PC12 cells but was
454 specifically induced by a 10-day NGF treatment,
455 suggesting a role in the control of neuronal dif-
456 ferentiation. Both UDP-glucose and LTD4
457 induced a significant pro-survival effect on
458 PC12 cells. By in vitro silencing experiments
459 with small interfering RNAs and by using recep-
460 tor antagonists, these effects were confirmed to
461 be mediated by the selective activation of
462 GPR17. In differentiated PC12 cells,
463 UDP-glucose and LTD4 caused a significant
464 increase in extracellular signal–regulated kinases
465 1 and 2 (ERK1/2) phosphorylation. ERK activa-
466 tion induced by the two agonists occurred with
467 different kinetics: LTD4 induced a transient ERK
468 activation that returned to basal value within
469 120 min. In contrast, ERK phosphorylation
470 induced by UDP-glucose was maintained over
471 basal values for 120 min and the activation kinet-
472 ics appeared to be biphasic with two peaks, one
473 at 15 and the other one at 120 min. In addition,
474 incubation of cells with the purinergic antagonist
475 cangrelor completely counteracted UDP-glucose
476 effects at all tested incubation times (Daniele
477 et al. 2010). These data confirmed the responses
478 to uracil nucleotides and cysLTs already seen on
479 the recombinant receptors, and suggested, for the
480 first time, that endogenous GPR17 ligands can
481 couple to distinct G proteins and intracellular
482 pathways, a finding that was later confirmed by
483 other studies (Hennen et al. 2013; Daniele et al.
484 2014). The signaling pathways of native GPR17
485 are summarized in Table 1.
486 In 2011, in another study that independently
487 confirmed the purinergic component of GPR17,
488 Buccioni and coworkers (Buccioni et al. 2011)
489 exploited an innovative and non-radioactive
490functional cAMP assay to monitor GPR17 acti-
491vation (and the effects of various ligands)
492through changes in intracellular cAMP
493concentrations by using a mutant form of
494Photinus pyralis luciferase into which a cAMP-
495binding protein moiety had been inserted
496(GloSensor cAMP reagent). In HEK293 cells
497stably transfected with the GloSensor reagent,
498transient expression of hGPR17 resulted in the
499appearance of highly specific concentration-
500dependent responses to both UDP,
501UDP-glucose and UDP-galactose and to a series
502of UDP and ATP derivatives that behaved as
503either agonist or antagonists, with EC50 values
504that were very similar to those obtained in paral-
505lel on [35S]GTPγS binding. In this system,
506cysLTs were not tested, due to the high constitu-
507tive expression of traditional CysLT receptors in
508the HEK293 cells (Ciana et al. 2006; Buccioni
509et al. 2011).
5102.2.2
511
2GPR17 Non-conventional Ligands
513In the last years, the increasing number of class-
514A GPCR solved structures allowed the scientific
515community to recognize some common features
516that are crucial for their operability (Levit et al.
5172014); however, these studies also revealed an
518unexpected heterogeneity and complexity in
519GPCR recognition, challenging the classical
520pharmacology paradigms of the ‘monogamous’
521interaction between a specific class of natural
522ligands and a single GPCR (Haupt et al. 2013).
523In line with the growing promiscuity of GPCRs,
524ligand dependent transactivation has been
525demonstrated for GPR17, already known as a
526“dual” receptor: similarly to EBI2 (Hannedouche
527et al. 2011; Liu et al. 2011a), and the CXC
528chemokine receptor 2 (CXCR2) (Raccosta et al.
5292013). Specifically, it was shown that, GPR17
530could act as a molecular target for oxysterols,
531oxidized derivative of cholesterol that, in the
532CNS, are involved in activities not strictly
533associated with cholesterol metabolism. Of
534note, these activities are particularly relevant
535for neurodegenerative disorders, including
536demyelinating (Raccosta et al. 2013; Garenc
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537 et al. 2010). More in detail, three selected
538 oxysterols (27-Hydroxycholesterol, 7
539 α-Hydroxycholesterol and 22R–Hydroxycho-
540 lesterol) were tested in 1321N1 cells stably
541 expressing GPR17, showing that all the tested
542 compounds were able to stimulate GTPγS bind-
543 ing, in a concentration-dependent manner, with
544 EC50 values of 4.99  0.78 nM, 0.70  0.09 nM
545 and 0.21  0.03 nM, for 27-Hydroxycholesterol,
546 7α-Hydroxycholesterol and 22R–Hydroxycho-
547 lesterol, respectively.
548 Stimulus of cell membranes with different
549 oxysterol concentrations after treatment with
550 the purinergic ligand UDP-glucose showed a
551 left-shift of the concentration-response curves
552 or an enhancement of their maximal [35S]
553 GTPγS binding stimulation, suggesting that
554 these ligands may cooperate under
555 neuroinflammatory conditions.
556 In parallel, the effect of different concentra-
557 tion of the GPR17 receptor antagonist cangrelor
558 on oxysterol-stimulated [35S]GTPγS binding was
559 evaluated, demonstrating that cangrelor can
560 counteract GPR17 activation by oxysterols
561 through a competitive mechanism, with IC50
562 values in a sub-nM range. These results are also
563 in agreement with in silico data suggesting a
564 common orthosteric molecular recognition
565 mechanism for oxysterols and other small
566 GPR17 ligands, despite different local
567 arrangements in the TM binding site (Sensi
568 et al. 2014).
569 Among other non-conventional ligands, fur-
570 ther evidence showed that SDF-1, historically
571 known as the endogenous ligand for CXCR4
572 and CXCR7 receptors, is able to transactivate
573 GPR17 in vitro, specifically increasing the [35S]
574 GTPγS binding to membrane of GPR17-
575 expressing cells, with affinity constant values of
576 0.14  0.03 nM. The effect of SDF-1 in
577 modulating GPR17 responses in vitrowas further
578 assessed in primary OPC cultures natively
579 expressing GPR17. In this model, treatment
580 with physiological concentrations of SDF-1 sig-
581 nificantly increased the number of cells
582 expressing the Myelin Basic Protein MBP com-
583 pared to control, thus accelerating OPC differen-
584 tiation towards a mature phenotype. The specific
585involvement of GPR17 in these effects was
586unequivocally demonstrated by further
587experiments showing that, in presence of the
588GPR17 antagonist cangrelor, SDF-1 induced no
589increases of either [35S]GTPγS binding to cell
590membranes, or MBP-expression in OPC cultures.
591Moreover, the mechanism by which GPR17 and
592SDF-1 can directly interact to each other has
593been predicted and extensively characterized in
594silico through molecular modeling (Parravicini
595et al. 2016).
596These results are in line with literature data,
597that propose a role of SDF-1 in orchestrating
598OPC differentiation and maturation also via
599CXCR4/CXCR7-axis (Li et al. 2012; Patel et al.
6002010; Carbajal et al. 2011).
601Interestingly, not only GPR17, CXCR4 and
602CXCR7, but also others chemokine receptors,
603like CXCR2, have demonstrated roles in
604regulating OPCs. As previously mentioned (see
605Sect. 2.1), besides sharing the same ligands,
606GPR17 and chemokine receptors are phylogen-
607etically related to each other, and all participate
608to CNS reparative responses. This raises the
609hypothesis that, under neurodegenerative demy-
610elinating conditions, oxysterols and other
611pro-inflammatory ligands, such as SDF-1, act as
612non-conventional molecules with a transversal
613regulatory role, representing a conserved,
614“unspecific” signaling mechanism, by which
615emergency molecules synchronize multiple
616receptors involved in inflammatory/immune
617responses.
6182.2.3
619
20New GPR17 Synthetic Ligands
621In 2009 and 2010, two papers reported the devel-
622opment of a new FAC-MS binding method for
623the analysis of GPCRs (Calleri et al. 2010;
624Temporini et al. 2009). In this assay, UDP was
625found to bind to GPR17 with a Kd value of
6261612.0  708 nM that was very similar to the
627Kd value (1140.0 nM) obtained by Ciana et al.
628and Lecca et al. in the [35S]GTPγS-binding
629(Ciana et al. 2006; Lecca and Ceruti 2008).
630This paper also unveiled a number of previously
631unreported GPR17 ligands, some of which were
632able to increase [35S]GTPγS binding, with
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633 potency values in the μM and sub-nM range. For
634 example, the ATP analogue 2-Phenylethynyla-
635 denosine-50-monophosphate Compound N.AU2 4
636 behaved as a very potent agonist with an EC50
637 value of 36 pM. In contrast, other ligands (e.g.: N
638
6-Benzoyl-20-deoxyadenosine 30,50-Bis phos-
639 phate, referred by the authors as Compound
640 N. 12) did not induce any increase in [35S]
641 GTPγS binding, but counteracted stimulation
642 induced by UDP-glucose with an antagonist pro-
643 file and an affinity constant in the nM range
644 comparable to that reported for its analogue
645 derivative MRS2179. Both the newly identified
646 agonists and antagonists displayed similar
647 behavior in the FAC-MS binding assay (Calleri
648 et al. 2010). A comparison between these data
649 and [35S]GTPγS binding results have been also
650 reported in a recent review article on GPR17
651 (Marucci et al. 2016).
652 In the same year, an advanced in silico HM
653 procedure combined with high-efficiency virtual
654 screening of more than 120,000 compounds from
655 the Asinex Platinum Collection (http://www.
656 asinex.com/), a lead-like structural library, on
657 the modeled receptor led to the selection of
658 5 chemically diverse molecules (the ASINEX
659 compounds, see Fig. 3 for the chemical structure
660 of one representative compound,
661 2-[[5-(2-Methoxyphenyl)-4-(4-methoxyphenyl)-
662 4H-1,2,4-triazol-3-yl]thio]-N-phenylpro-
663 panamide, also referred as ASN 1), that were
664 completely unrelated to already known ligands.
665 These compounds were tested in vitro in the [35S]
666 GTPγS binding assay, revealing a sub-nM
667 potency for GPR17 (Eberini et al. 2011) (see
668 also below). None of these compounds could
669 have been expected ‘a priori’ to act on GPR17,
670 and all of them behaved as much more potent
671 ligands than GPR17 endogenous activators
672 (Eberini et al. 2011). Finally, in 2013,
673 MDL29,951 was reported as an additional small
674 molecule agonist at GPR17 (Hennen et al. 2013)
675 (Fig. 3). In a variety of different heterologous
676 expression systems, MDL29,951-stimulated
677 GPR17 engaged the entire set of intracellular
678 adaptor proteins for GPCRs: G proteins of the
679 Gαi, Gαs, and Gαq subfamily, as well as
680 β-arrestins. This was visualized as alterations in
681the concentrations of cyclic adenosine
682monophosphate and inositol phosphate,
683increased Ca2+ flux, phosphorylation of ERK1/
6842, as well as multifeatured cell activation
685recorded with label-free dynamic mass redistri-
686bution and impedance biosensors. pEC50 values
687for MDL29,951 at GPR17 ranged between 5 and
6888.80, depending upon the transfected cell type
689and the used read out. MDL29,951-stimulated
690GPR17 effects were counteracted in a
691concentration-dependent manner by pranlukast
692and, to a lesser extent, by montelukast. This is
693fully in line with the activities of these
694antagonists on recombinant GPR17 in previous
695studies, in which pranlukast was significantly
696more potent than montelukast in antagonizing
697LTD4-stimulation of GPR17 (Ciana et al.
6982006). In OPCs, MDL29,951 rapidly mobilized
699intracellular Ca2+ in a concentration-dependent
700manner and engaged both Gαi and Gαq, but not
701Gαs signaling pathways, further suggesting
702differences in GPR17 responses between
703transfected and native systems (see also
704Conclusions). This is at variance from previous
705studies reporting Gαi coupling and decreases of
706intracellular cAMP as a primary transduction
707pathway of GPR17 in OPCs (Daniele et al.
7082014; Fumagalli et al. 2011b). However, it has
709to be emphasized that, despite being selective for
710GPR17 inside the “purine receptor cluster”
711(Hennen et al. 2013), MDL29,951 also signifi-
712cantly interacts with the glycinergic site of the
713glutamate NMDA receptor (Salituro et al. 1992).
714This may be at the basis of the ability of
715MDL29,951 to activate multiple signaling
716pathways in both transfected cells and in OPCs,
717and of the data reported for this compound on
718myelination (see also Sect. 3.1.1).
7192.2.4
720
21Agonist-Induced Desensitization
2and Internalization
723In 2011, the first complete agonist-induced
724GPR17 desensitization/resensitization study was
725published (Daniele et al. 2011). By using [35S]
726GTPγS binding and cAMP measurements in
7271321N1 cells expressing hGPR17, both
728UDP-glucose and LTD4 were shown to induce a
729time- and concentration-dependent loss of
Pharmacological Properties and Biological Functions of the GPR17 Receptor, a. . .
730 GPR17 response (homologous desensitization).
731 GPR17 homologous desensitization was
732 accompanied by internalization of receptors
733 inside cells, as assessed by biotin labeling of
734 cell surface receptors. Desensitization occurred
735 in a time-dependent manner, with similar kinet-
736 ics for both agonists. Upon agonist removal,
737 receptor resensitization occurred with the typical
738 kinetics of GPCRs. Finally, activation of GPR17
739 by UDP-glucose induced a partial heterologous
740 desensitization of LTD4-mediated responses (but
741 not vice versa), suggesting that nucleotides have
742 a hierarchy in producing desensitizing signals.
743 The pattern of GPR17 desensitization and
744 internalization was fully confirmed and further
745 expanded in differentiated oligodendroglial
746 Oli-neu cells that natively express GPR17
747 (Fratangeli et al. 2013) (Table 1). Agonist-
748 induced internalization, intracellular trafficking
749 and membrane recycling of GPR17 were
750 analyzed by biochemical and immunofluores-
751 cence assays using an ad hoc-developed new
752 antibody against the extracellular N-terminal of
753 GPR17. Both UDP-glucose and LTD4 increased
754 GPR17 internalization, although with different
755 efficiency. At early time points, internalized
756 GPR17 co-localized with transferrin receptor,
757 whereas at later times it partially co-localized
758 with the lysosomal marker Lamp1, suggesting
759 that a portion of GPR17 is targeted to lysosomes
760 upon ligand binding. Internalization of GPR17
761 occurred via clathrin-dependent endocytosis
762 (Fratangeli et al. 2013). Analysis of receptor
763 recycling and degradation demonstrated that a
764 significant fraction of GPR17 is recycled to the
765 cell surface. These results provided the first data
766 on the agonist-induced trafficking of native
767 GPR17 in oligodendroglial cells and may have
768 implications in fine-tuning cell responses to
769 demyelinating and inflammatory conditions
770 when these ligands accumulate at lesion sites
771 (see also Sect. 3.1.2). More recently, GPR17
772 downregulation by uracil nucleotides and cysLTs
773 was confirmed in primary cultured OPCs, and the
774 role of the GRK/β-arrestin machinery in receptor
775 desensitization and intracellular signaling was
776 also extensively investigated (Daniele et al.
777 2014). It was shown that, following OPCs
778treatment with the two classes of purinergic and
779cysLT ligands, different GRK isoforms were
780recruited. Specifically, cysLT-mediated GPR17
781desensitization mainly involved GRK2 via a G
782protein-dependent mechanism (Daniele et al.
7832014). This kinase promoted transient binding
784of the receptor to β-arrestins, rapid ERK phos-
785phorylation and sustained nuclear CREB activa-
786tion. Furthermore, GRK2, whose expression
787paralleled that of the receptor during the differ-
788entiation process, was required for cysLT-
789mediated OPCs maturation (see also Sect. 3.2.).
790On the other hand, purinergic ligands exclusively
791recruited GRK5 via a G protein-
792independent/β-arrestin-dependent mechanism.
793This kinase induced a stable association between
794the receptor and β-arrestin, followed by slower
795and sustained ERK stimulation and marginal
796CREB activation (Daniele et al. 2014). These
797results show that, through activation of GPR17
798and recruitment of specific GRK isoforms,
799purinergic and cysLT ligands engage distinct
800intracellular pathways.
801Recently GPR17 desensitization (and its rela-
802tionship to terminal OPC maturation) has been
803linked to activation of mTOR (the “mammalian
804target of rapamycin”), which has long been
805known to be involved in myelination. During
806OPC differentiation, mTOR regulates
807GRK-mediated desensitization of GPR17 by pro-
808moting the nuclear translocation of the ubiquitin
809ligase MDM2, which had been previously only
810involved in cancer via regulation of p53 activity
811and now emerges as a new interesting actor in
812oligodendrogenesis (Fumagalli et al. 2015). Spe-
813cifically, treatment of OPCs with either the
814mTOR inhibitor rapamycin, or with nutlin-3, a
815small molecule inhibitor of Mdm2-p53
816interactions, was shown to keep MDM2 in the
817cytosol, where it could bind to GRK2 and sustain
818its degradation, thus impairing the physiological
819desensitization of GPR17 (Fumagalli et al.
8202015). Important, prevention of GPR17 desensi-
821tization was also associated to a defect of OPC
822maturation, confirming that aberrantly elevated
823GPR17 levels in late stage OPCs blocks cells at
824immature stages (Fumagalli et al. 2015).
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825 In another study, GPR17 plasma membrane
826 recycling and stability was shown to be also
827 modulated by SNX27, a recently identified pro-
828 tein of the endosome-associated retromer com-
829 plex, whose functions in oligodendrocytes had
830 never been studied. It was found that, after endo-
831 cytosis, GPR17 is either sorted into lysosomes
832 for degradation or recycled to the plasma mem-
833 brane. Balance between degradation and
834 recycling was important for modulation of recep-
835 tor levels at the cell surface, and thus for the
836 silencing or maintenance of GPR17-signaling
837 pathways, that, in turn, affect OPC differentia-
838 tion (see also Sect. 3.2). The endocytic traffick-
839 ing of GPR17 was mediated by interaction of
840 SNX27 with a type I PDZ-binding motif located
841 at the C-terminus of the receptor. Of note,
842 SNX27 knock-down reduced GPR17 plasma
843 membrane recycling in differentiating oligoden-
844 drocytes while accelerating terminal cell matura-
845 tion. Interestingly, trisomy-linked down-
846 regulation of SNX27 in the brain of Ts65Dn
847 mice, a model of Down syndrome, correlated
848 with a dysfunction in GPR17+ cells and an
849 increase in mature oligodendrocytes, which,
850 however, failed in reaching full maturation,
851 eventually leading to hypomyelination
852 (Meraviglia et al. 2016). Thus, disruption of
853 SNX27/GPR17 interactions leading to
854 alterations of GPR17 membrane trafficking
855 might contribute to pathological oligodendrocyte
856 differentiation and myelination defects present in
857 Down syndrome (Meraviglia et al. 2016).
3858 Role of GPR17 in Central
859 Nervous System
860 Pathophysiology
3.1861 GPR17 Specific Roles
862 in Oligodendroglial Functions
863 and Myelination
864 3.1.1
865
6 Physiological Roles
867 In the healthy intact brain, GPR17 expression is
868 predominantly in oligodendrocyte (OL) cells.
869 The very first demonstration that, in the adult
870brain, GPR17 is highly expressed by a
871sub-population of endogenous quiescent paren-
872chymal OPCs dates back to 2008 (Lecca et al.
8732008) and has sparked a lot of interest on GPR17
874role in CNS myelination. Specifically, GPR17
875was shown to be present in ramified early neural
876cell precursors dispersed throughout brain’s gray
877and white matter that also positively stained for
878typical early OPC markers. Since then, increas-
879ing evidence has progressively accumulated to
880show a pivotal role of GPR17 in OPC matura-
881tion, with different and apparently paradoxical
882effects during different phases of the maturation
883process (Chen et al. 2009; Fumagalli et al.
8842011a) (see also below).
885In vitro studies on purified rat postnatal OPC
886cultures showed that GPR17 expression
887coincides with a specific temporal window of
888the OL differentiation process. It covers two
889distinct phases: a first phase, during which early
890differentiation markers like NG2, A2B5, PDGF
891receptor-alpha and the immature PLP isoform
892DM-20 are still present (early stage 2 OPCs in
893Fig. 4), and a subsequent phase characterized by
894more ramified, still immature
895pre-oligodendrocytes (stages 3 and 4 in Fig. 4),
896where NG2 has been downregulated and more
897advanced markers like O4, O1 and the
898proteolipid myelin protein PLP are present
899(Fumagalli et al. 2011a). Based on these data,
900GPR17 is currently utilized by other independent
901scientists to specifically label pre-immature OLs
902at these two transition stages (Mitew et al. 2013;
903Nakatani et al. 2013; Crociara et al. 2013; Ferrara
904et al. 2016).
905Of note, GPR17 expression progressively
906increases during the transition of OPCs to
907pre-OLs (when it is maximally expressed in cel-
908lular processes), but is then gradually silenced
909and never found in fully morphologically mature
910OLs (Fumagalli et al. 2011a) (see Fig. 4).
911Accordingly, in vivo, GPR17 is present in a sub-
912set of NG2/Olig2-positive OPCs expressing the
913first myelin proteins, but not in more mature cells
914expressing myelin basic protein (MBP). Also
915during rodent brain development, GPR17 expres-
916sion in OPCs precedes myelin production. Inter-
917estingly, GPR17 immunoreactivity appears first
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918 in the cell body, partially coinciding with
919 markers of the Golgi apparatus, and then gradu-
920 ally extends to cellular processes (Boda et al.
921 2011). Early after birth, the expression of the
922 receptor is low, but progressively expands to
923 cover the 80% of OPCs at the end of the third
924 week of life. Afterwards, GPR17 is down-
925 regulated while myelination proceeds (Boda
926 et al. 2011).
927 The transient nature of GPR17 expression in
928 OPCs suggests that the receptor may display
929 stage-specific roles during OL development.
930 Intriguingly, as already reported for the
931 Wnt/β-catenin pathway (Fancy et al. 2009; Ye
932 et al. 2009) and more recently proposed for the
933 transcription factor Olig2 (Mei et al. 2013),
934 GPR17 exhibits opposing functions on OL dif-
935 ferentiation in relation to its expression stage. In
936 cultured cortical postnatal rat OPCs, early recep-
937 tor obliteration with small interfering RNAs
938profoundly affected their ability to generate
939mature OLs, suggesting that cells are retained at
940a less differentiated stage (Fumagalli et al.
9412011a) (Fig. 4). Although the molecular
942mechanisms at the basis of these events have
943not been yet investigated, these data highlight a
944pivotal role of GPR17 in the initial phases of the
945differentiation process. They support the hypoth-
946esis that, at these stages, GPR17 may be impor-
947tant to keep cells at an immature state which
948may, in turn, be necessary to prepare them for
949myelination (Fumagalli et al. 2011a). In contrast,
950cultured cortical progenitors from GPR17 knock-
951out E15.5 mouse embryos differentiated earlier
952toward mature OLs compared to control cells
953(Chen et al. 2009). The reasons for these
954discrepancies remain unknown, although it may
955be hypothesized that compensatory mechanisms
956are activated as a result of early embryonic
957GPR17 knock out. Of course, the generation of
Fig. 4 Transient GPR17 expression during oligoden-
droglial differentiation. The expression pattern of
GPR17 (in red) during oligodendroglial differentiation
is shown in parallel to other known oligodendroglial
markers (other colours). Progressive differentiation stages
are indicated with numbers from 1 to 5. From a functional
point of view, GPR17 exerts opposing stage-specific
roles: a positive role for differentiation in early OPCs
and a negative function for OL maturation in late OPCs.
In late OPCs, gradual silencing of GPR17 is needed to
allow OPCs to complete their maturation (see text for
more details)
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958 conditional transgenic mice in which deletion of
959 GPR17 in OPCs could be induced under con-
960 trolled conditions at specific ages will help
961 clarifying this issue.
962 Lecca and coworkers also clearly showed that
963 GPR17 is no longer present in morphologically
964 mature MBP-positive cells (Lecca et al. 2008),
965 raising for the first time the possibility that loss of
966 GPR17 at advanced differentiation stages is a
967 prerequisite to allow cells to complete terminal
968 maturation. Subsequent in vivo data showed that
969 myelinogenesis is indeed defective in transgenic
970 mice overexpressing GPR17 under the promoter
971 of 20,30-Cyclic-nucleotide 30-phosphodiesterase
972 (CNPase), a relatively advanced OL marker
973 (Chen et al. 2009). These animals exhibited
974 motor disabilities, tremors and precocious death
975 within the second week of life. The forced and
976 un-timely expression of GPR17 at a maturation
977 stage (i.e., in CNPase+ cells), at which GPR17 is
978 normally already downregulated, might have cre-
979 ated conflicting signals leading to defective ter-
980 minal maturation. Thus, interference with the
981 stage-restricted expression of GPR17 resulting
982 in un-programmed receptor expression in late
983 OPCs completely alters the differentiation pro-
984 gram of these cells. This hypothesis is fully in
985 line with the demonstration that OPCs
986 incorporating a vector for GPR17 over-
987 expression maintained an immature morphologi-
988 cal phenotype and never expressed the mature
989 marker CNPase, and with data showing that,
990 under conditions where terminal OPC maturation
991 is impaired, such as demyelinating diseases (see
992 Sect. 3.1.2) or treatment with the mTOR inhibi-
993 tor rapamycin, that reduces OPC maturation,
994 GPR17 is markedly up-regulated (Fumagalli
995 et al. 2015; Tyler et al. 2011).
996 Both intrinsic and extrinsic mechanisms could
997 contribute to GPR17 stage-specific functions
998 during oligodendrocyte differentiation. GPR17
999 can be extrinsically regulated by physiological
1000 ligands accumulating in the extracellular milieu:
1001 activation of early OPCs (stages 2 and 3 in Fig. 4)
1002 with GPR17 endogenous putative ligands (i.e.,
1003 UDP-glucose or LTD4) indeed promoted conver-
1004 sion to more mature cells expressing myelin
1005markers (Lecca et al. 2008; Fumagalli et al.
10062011a; Ceruti et al. 2011). Consistent with these
1007data, GPR17 antagonists like cangrelor (Fig. 3)
1008delayed the ability to generate mature cells
1009(Lecca et al. 2008; Fumagalli et al. 2011a),
1010suggesting that GPR17 endogenous ligands are
1011basally released in culture and are responsible for
1012the observed spontaneous OPC in vitro matura-
1013tion. In another independent study, while not
1014modifying the potential of adult multipotent neu-
1015ral stem cells, montelukast, which also acts as a
1016GPR17 antagonist (Ciana et al. 2006; Benned-
1017Jensen and Rosenkilde 2010; Lecca et al. 2008),
1018markedly increased their proliferation rate,
1019suggesting that GPR17 antagonism induces
1020retention of cells at a more undifferentiated
1021stage (Huber et al. 2011).
1022As already mentioned, besides cAMP inhibi-
1023tion, GPR17 has been also shown to specifically
1024mediate activation of delayed rectifier K+
1025currents (Table 1) in a sub-population of OPCs
1026and O4+ pre-OLs, but not in mature OLs. This
1027effect was shown to contribute to the terminal
1028maturation of OPCs and to their migratory
1029abilities.
1030In contrast with the above studies,
1031MDL29,951, the new putative GPR17 agonist
1032mentioned above, was reported to inhibit, rather
1033than stimulate, OL maturation (Hennen et al.
10342013). However, it is worth to note that, due to
1035the transient expression of GPR17 in culture, the
1036timing of OPC manipulation and treatment is
1037crucial for obtaining comparable results. On the
1038other hand, as already mentioned, MDL29,951 is
1039not a selective ligand for this receptor, and inde-
1040pendent effects could be due to its antagonistic
1041activity at the glycinergic site of the glutamate
1042NMDA receptor (Salituro et al. 1992), which has
1043been indeed reported to promote OPC differenti-
1044ation (Li et al. 2013).
1045Globally, these findings suggest that GPR17
1046exerts opposing stage-specific roles: a positive
1047role for differentiation in early OPCs and a nega-
1048tive function for OL maturation in late OPCs.
1049They also suggest that, in late OPCs, physiologi-
1050cal GPR17 silencing is needed to allow cells to
1051complete their maturation program. The latter
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1052 may occur via either GPR17 desensitization/
1053 internalization by endogenous agonists or by
1054 GPR17-mediated engagement of intracellular
1055 pathways culminating in nuclear events, or
1056 both. Blockade of GPR17 mRNA translation
1057 into the receptor protein a specific microRNA
1058 has been also recently reported to contribute to
1059 GPR17 regulation during OPC maturation
1060 (Lecca et al. 2016).
1061 3.1.2
1062
3 Dysregulation in Demyelinating
4 Neurodegenerative Diseases
1065 The demonstration that levels of endogenous
1066 nucleotides and cysLTs are massively increased
1067 upon CNS trauma and ischemia and their
1068 hypothesized roles as danger signals after injury
1069 (Davalos et al. 2005; Haynes et al. 2006) has
1070 raised the hypothesis that GPR17 may act as a
1071 crucial mediator of reactivity to acute injury.
1072 While physiologically GPR17 is mostly an
1073 oligodendroglial receptor, after acute injury,
1074 GPR17 is sequentially induced in dying neurons
1075 inside and at the borders of the ischemic/trau-
1076 matic lesion, in infiltrating microglia/
1077 macrophages and in activated parenchymal
1078 OPCs in the lesion’s surrounding areas, with
1079 similar expression patterns in different models
1080 of pathology. In more detail, in both rats and
1081 mice, 24 h after permanent middle cerebral artery
1082 occlusion (MCAo), GPR17 is up-regulated in
1083 neurons damaged by the ischemic insult inside
1084 the ischemic core (Ciana et al. 2006; Lecca et al.
1085 2008). When the penumbra area is well visible
1086 and most of the neurons in the core are dead,
1087 GPR17 appears on highly activated microglia
1088 and blood-borne macrophages at the borders of
1089 the lesion (Lecca et al. 2008). This has been
1090 independently confirmed to also occur in a tran-
1091 sient MCAo rodent model, where the number of
1092 GPR17 expressing cells was significantly
1093 upregulated in two distinct phases, 24 h and
1094 7 days after reperfusion, consistent with an
1095 early acute neuronal injury followed by a late
1096 microgliosis (Zhao et al. 2012). It is known that
1097 OPCs are extremely sensitive to the pathophysi-
1098 ological state of the brain, and that they react to
1099 many different types of experimentally induced
1100 insults. Starting from 72 h after the insult, in the
1101regions surrounding the ischemic area and in the
1102ipsilateral corpus striatum of MCAo mice, a
1103higher number of GPR17-expressing OPCs was
1104indeed found compared to contralateral hemi-
1105sphere (Lecca et al. 2008), suggesting an
1106increased proliferation rate in response to
1107demyelination.
1108Dysregulated expression of GPR17 has been
1109described also after traumatic injury, in both
1110brain (Boda et al. 2011) and spinal cord (Ceruti
1111et al. 2009). In stab wound, a model of cortical
1112trauma, early after lesion, the density of GPR17-
1113expressing OPCs in gray matter was reduced
1114compared to contralateral cortex, consistent
1115with a global oligodendroglial loss. At later
1116times, GPR17+ cells increased significantly in
1117number around the lesion in both gray and
1118white matter, likely due to the expansion of the
1119NG2 cell pool, which, in turn, reflects an attempt
1120to replace dead OPCs. This reactivity lasted up to
11217 days and then declined over time, going back to
1122basal levels at 14 days after lesion. This pattern
1123has been confirmed in human samples from
1124patients with traumatic brain injury (Franke
1125et al. 2013). In both neurosurgical and autopsy
1126specimens, GPR17 expression was evident inside
1127the contused core and progressively declined
1128distally according to a spatio-temporal gradient.
1129Inside and around the core, GPR17 labeled dying
1130neurons, reactive astrocytes, and activated
1131microglia/macrophages. In peri-contused paren-
1132chyma, GPR17 was found on OPCs, some of
1133which had proliferated, indicating
1134re-myelination attempts. In agreement with the
1135above data, in a double transgenic model of
1136Alzheimer’s disease (the APPPS1 mouse) a
1137high number of GPR17-positive cells
1138accumulated close to amyloid plaques in gray
1139matter, revealing receptor up-regulation as a fea-
1140ture of oligodendroglial reactivity also in this
1141pathological condition (Boda et al. 2011).
1142Similar GPR17 changes have been reported
1143also in typically de-myelinating diseases such as
1144in models of multiple sclerosis (MS). In this
1145disease, remyelination occurs after the initial
1146myelin damage, but it fails after multiple demye-
1147lination episodes, which eventually leads to axo-
1148nal degeneration and progressive disability
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1149 (Franklin and Ffrench-Constant 2008). Interest-
1150 ingly, synthesis of cysLTs is increased in MS
1151 plaques and in the spinal cord of mice subjected
1152 to experimental autoimmune encephalomyelitis
1153 (EAE), an immune-mediated model of demyelin-
1154 ation (Whitney et al. 2001). Of note,
1155 montelukast, an antagonist at both CysLT1 and
1156 GPR17, attenuated CNS infiltration of inflamma-
1157 tory cells and the clinical symptoms of EAE
1158 (Wang et al. 2011). However, the exact contribu-
1159 tion of GPR17 to these effects has not been
1160 investigated in detail. Overexpression of the
1161 GPR17 transcript has been observed in both
1162 EAE mice and in a cohort of human MS tissues
1163 (Chen et al. 2009). GPR17 expression was sig-
1164 nificantly increased in MS plaques as compared
1165 with white matter from non-neurological donor
1166 samples and normal-appearing white matter from
1167 MS donors. In a similar way, acute damage to
1168 myelin induced by lysolecithin (Lys) injection in
1169 corpus callosum induced a strong overexpression
1170 of GPR17 at the lesion site 10 days after injury
1171 (Boda et al. 2011). Thus, independently of the
1172 original cause, GPR17 is abnormally
1173 up-regulated in MS and some models of neuro-
1174 degenerative conditions characterized by myelin
1175 disruption (Fumagalli et al. 2016).
1176 On this basis, it could be hypothesized that,
1177 after damage, GPR17 is initially induced to pro-
1178 mote the growth and differentiation of OPCs;
1179 however, at later stages, due to lack of appropri-
1180 ate environmental stimuli, presence of inflamma-
1181 tory signals and/or intrinsic factors,
1182 physiological GPR17 downregulation is
1183 impeded, thus freezing cells at a stand-by stage,
1184 where they are neither proliferating nor
1185 differentiating. When this happens, interventions
1186 targeting GPR17 may help bypassing this check-
1187 point and facilitate terminal maturation. Since
1188 GPR17 is a membrane receptor that, at variance
1189 from other intrinsic regulators of oligoden-
1190 drogenesis, can be easily targeted and
1191 manipulated with pharmacological agents, it is
1192 envisaged that agents counteracting GPR17 aber-
1193 rant expression under these conditions could
1194 induce OPCs to resume myelination and promote
1195 neurorepair. To support this hypothesis, in
1196 MCAo animals, administration of GPR17
1197antagonists such as cangrelor or montelukast
1198(Ciana et al. 2006; Lecca et al. 2008), or
1199GPR17 silencing due to in vivo delivery of spe-
1200cific antisense oligonucleotides (Ciana et al.
12012006; Lecca et al. 2008) or small interfering
1202RNAs (Zhao et al. 2012) resulted in a significant
1203reduction in brain’s ischemic volume. Use of
1204GPR17 anti-sense oligonucleotides also reduced
1205damage and improved functional recovery in a
1206model of spinal cord injury, in line with the
1207hypothesis that GPR17 is aberrantly
1208overexpressed as a consequence of damage
1209(Ceruti et al. 2009).
1210In contrast to what observed in MCAo, in a rat
1211neonatal model of ischemic periventricular
1212leukomalacia (PVL), a common cerebral white
1213matter injury, the GPR17 agonist UDP-glucose
1214(and not an antagonist) significantly contributed
1215to myelin sheaths recovery and improved motor
1216functions, learning and coordination in PVL pups
1217(Mao et al. 2012). The reason for this discrep-
1218ancy may reside in the different outcome of the
1219ischemic insult in neonatal brain compared to
1220adults. It could be hypothesized that, in neonatal
1221pups, existing OPCs, which are very sensitive to
1222ischemic death, are immediately killed by the
1223ischemic insult, with no obvious GPR17
1224upregulation; conversely, being these cells
1225generated at distinct waves during the first
1226weeks of life at much higher rates compared to
1227adulthood, a GPR17 agonist (instead of an antag-
1228onist) would allow to properly activate newborn
1229OPCs, thus favouring the formation of myelin
1230sheaths and neurological recovery.
1231Several of the still obscure aspects of GPR17
1232pathophysiology have been linked to the diffi-
1233culty of establishing a causal relationship
1234between GPR17 expression and myelination
1235in vivo. Since GPR17 is no longer expressed in
1236mature myelinating OLs (Lecca et al. 2008;
1237Fumagalli et al. 2015), it was impossible to dem-
1238onstrate that cells that have expressed GPR17 in
1239their earlier life can indeed myelinate. Only
1240recently, the generation of the first
1241GPR17iCreERT2-GFP reporter mouse line for
1242fate mapping studies has allowed to follow the
1243final destiny of GPR17+ cells during both physi-
1244ological differentiation and in disease, thanks to
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1245 the inducible expression of the green fluores-
1246 cence protein (GFP). In these mice, upon tamox-
1247 ifen induced recombination, OPCs expressing
1248 GPR17 at that very specific moment, become
1249 green and can be traced as such for the entire
1250 animal’s like. Use of these mice has allowed to
1251 show that, in normal brain, GFP+ cells differenti-
1252 ate very slowly (needing about 3 months to reach
1253 maturity), but after acute insults, they rapidly
1254 reacted to damage with proliferation and migra-
1255 tion toward the injured site, thus representing a
1256 ‘reserve pool’ of adult quiescent progenitors
1257 maintained for repair purposes (Vigano et al.
1258 2016). A full characterization of the long-term
1259 events occurring in the brain of ischemic MCAo
1260 GPR17iCreERT2-GFP mice has shown that,
1261 despite massive recruitment of GFP+ green
1262 OPCs at the ischemic site, only a few percentage
1263 of these cells become mature myelinating OLs,
1264 likely due to local unfavourable inflammatory
1265 milieu (Vigano et al. 2016; Bonfanti et al. 2017).
1266 More recently, it has been demonstrated that
1267 GPR17 over-activation inhibited oligodendro-
1268 cyte survival by reducing intracellular cAMP
1269 levels and inducing expression of the
1270 pro-apoptotic gene Xaf1. GPR17 overactivation
1271 also negatively regulated protein kinase A sig-
1272 naling pathway and expression of the transcrip-
1273 tion factor c-Fos. In line with these data, in the
1274 lysolecithin-mediated demyelination injury
1275 model, the pharmacological inhibition of
1276 GPR17 with pranlukast increased oligodendro-
1277 cyte survival and promoted immature oligoden-
1278 drocyte differentiation through the upregulation
1279 of Epac1, the exchange factor directly activated
1280 by cAMP (Ou et al. 2016). These data are fully
1281 consistent with our results in other injury models
1282 characterized by demyelination and abnormal
1283 GPR17 upregulation (summarized in Fumagalli
1284 et al. 2016), suggesting that under these
1285 conditions GPR17 inhibition has potential for
1286 treatment of demyelinating diseases (Ou et al.
1287 2016).
3.2 1288GPR17 in Brain Rejuvenation
1289A recent report has investigated the roles of
1290GPR17 in age-associated cognitive decline
1291(Marschallinger et al. 2015). Authors have first
1292shown that oral administration of montelukast
1293(an antagonist of both CysLTR1 and GPR17,
1294see above), for 6 weeks to moderately old rats
1295(20 months old) resulted in structural and func-
1296tional rejuvenation of aged brains, as
1297demonstrated by restoration of blood brain bar-
1298rier integrity, reduced microglia activation in the
1299brain, increased levels of hippocampal
1300neurogenesis and significantly improved learning
1301and memory tasks. Important, montelukast had
1302no effects on the behaviour and cognitive
1303abilities of young animals, suggesting that its
1304actions specifically target an aging associated
1305defect (see also below). Regression and correla-
1306tion analyses showed that montelukast-induced
1307learning improvement in the old animals was
1308independent of the changes in microglia mor-
1309phology but rather depended on the rate of
1310neurogenesis measured as increased number of
1311proliferating neuroblasts in hippocampal dentate
1312gyrus. Interestingly, authors also provided immu-
1313nohistochemical evidence for the presence of
1314GPR17, but not CysLTR1, in a subset of
1315doublecortin (DCX)+ newborn neurons in hippo-
1316campal dentate gyrus, suggesting a role in the
1317proliferation and specification of these cells.
1318Studies on neurospheres obtained from mice
1319lacking FOXO1, a GPR17 regulating transcrip-
1320tion factor, and from GPR17/ mice indeed
1321confirmed montelukast effects be due to action
1322on GPR17/DCX+ neuroblasts in hippocampal
1323dentate gyrus, leading to increased neurogenesis.
1324Globally these data suggest that, under normal
1325conditions, GPR17 exerts a negative control on
1326the proliferation of neural progenitors in the hip-
1327pocampus; in aged animals, due to the overall
1328decrease of neurogenesis, GPR17 inhibition of
1329proliferation becomes detrimental and
1330contributes to memory impairment. Under such
1331pathological conditions, montelukast can restore
1332neurogenesis by alleviating GPR17 inhibitory
1333effect (Marschallinger et al. 2015).
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3.31334 GPR17 in Gliomas
1335 OL markers such as Olig2, PDGFRα and NG2
1336 are often expressed in glioma cells. Little is
1337 known about the origin of these tumors, but it is
1338 possible that they arise from dysregulated OPCs
1339 (Liu et al. 2011b). Considering that OPCs are the
1340 only proliferating population in the adult brain,
1341 defects in differentiation mechanisms favouring
1342 cell proliferation could be a primary cause of
1343 gliomas. A complementary strategy for tumor
1344 treatment is to promote pathways for maintaining
1345 quiescence and/or driving terminal differentia-
1346 tion of the tumoral progenitors. In this respect,
1347 a recent microarray analysis of mouse and human
1348 gliomas aimed at unveiling new candidates pro-
1349 moting differentiation or quiescence has
1350 highlighted GPR17 as a new potential target
1351 (Dougherty et al. 2012). In glioma cells, treat-
1352 ment with UDP, UDP-glucose or LTD4 indeed
1353 reduced the formation of glioma spheres
1354 suggesting that GPR17 stimulation can represent
1355 a good strategy to drive the differentiation of
1356 highly proliferative uncommitted tumor cells to
1357 the oligodendroglial fate, negatively affecting
1358 both tumor cell proliferation and self-renewal
1359 (Dougherty et al. 2012). These data are in line
1360 with the fact that most of the OPCs expressing
1361 GPR17 in brain are quiescent (Lecca et al. 2008),
1362 and support the pro-differentiative effects of its
1363 putative endogenous ligands (see also Sects. 2.1
1364 and 3.2).
41365 Conclusions
1366 GPR17 has emerged as a new GPCR of great
1367 interest for drug development. It is almost exclu-
1368 sive localization to OPCs, the myelin forming
1369 cells and the only (slowly) proliferating cell pop-
1370 ulation in the intact brain, has highlighted
1371 GPR17 as a novel pharmacological target for
1372 demyelinating diseases. At variance from other
1373 myelinating genes, GPR17 is a membrane recep-
1374 tor, thus amenable for pharmacological modula-
1375 tion, which has attracted a lot of interest for the
1376 development of new therapeutic approaches to
1377MS and other neurodegenerative diseases
1378characterized by myelin disruption. The recent
1379demonstration that GPR17 is also expressed by a
1380subset of hippocampal neural progenitors
1381involved in cognitive functions does not detract
1382from the potential interest of GPR17 ligands in
1383neurodegenerative diseases, since, as
1384demonstrated by the montelukast study
1385(Marschallinger et al. 2015), these ligands may
1386be active only when specific pathological GPR17
1387changes are present.
1388The recent studies on GPR17 revealed its
1389transient expression in OPCs and a more com-
1390plex role than expected: a pro-differentiating role
1391in early OPCs and a negative function on matu-
1392ration in late stage OPCs. Thus, the apparently
1393contrasting in vitro data obtained with different
1394GPR17 stimulatory agents (Lecca et al. 2008;
1395Fumagalli et al. 2011a; Hennen et al. 2013)
1396may depend on the specific differentiation stage
1397at which these compounds have been added to
1398cultured OPCs. It may well be that the function
1399of GPR17 is different in the intact and diseased
1400brain, based on the availability of its endogenous
1401ligands. If uracil nucleotides, cysLTs, oxysterols
1402and chemokines like SDF-1 are indeed among
1403the signaling molecules able to activate GPR17
1404in vivo (see also below), we envisage that their
1405role would be more likely unveiled under patho-
1406logical conditions, where these ligands massively
1407accumulate at lesion sites inside the CNS.
1408Experiments in a wide variety of rodent
1409models of neurodegeneration have shown that,
1410independently of the nature of the insult (ische-
1411mic, traumatic or toxic) and of the presence of
1412any concomitant neuronal pathology, demyelin-
1413ating conditions invariably led to GPR17
1414upregulation. We believe that this dysregulation
1415reflects an initial attempt to repair the lesion by
1416stimulating OPCs differentiation via GPR17, but
1417that this attempt is later invalidated by the inabil-
1418ity of maturing cells to downregulate/internalize
1419the receptor, which, in turn, leads a differentia-
1420tion blockade. On this basis, it is envisaged that
1421GPR17 antagonists would be useful in MS and
1422neurodegenerative diseases. By counteracting
1423GPR17 aberrant dysfunction, antagonists would
1424help OPCs to complete their maturation, thus
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1425 re-establishing endogenous remyelination, as
1426 recently also confirmed (Ou et al. 2016).
1427 Due to the still ambiguous state of the phar-
1428 macology for this receptor, the Nomenclature
1429 Committee of the International Union of Phar-
1430 macology (NC-IUPHAR) has not yet officially
1431 de-orphanized this GPCR (Davenport et al.
1432 2013). However, as also emphasized by
1433 NC-IUPHAR, much of the work in this area has
1434 been based on recombinant expression systems
1435 using different host cells and transfection
1436 methodologies compared to data derived from
1437 native cells. In recombinant “artificial” cell
1438 systems, activity tests are highly dependent on
1439 the experimental conditions utilized and subject
1440 to several artifacts, especially in the case of
1441 receptors’ constitutive activation, a typical fea-
1442 ture of several GPCRs including GPR17
1443 (Benned-Jensen and Rosenkilde 2010; Maekawa
1444 et al. 2009; Qi et al. 2013; Eggerickx et al. 1995;
1445 Uhlenbrock et al. 2002; Rosenkilde et al. 2006;
1446 Qin et al. 2011; Im 2004) that can profoundly
1447 alter ligand behavior (Kenakin 2001; Davenport
1448 et al. 2013).
1449 In terms of drug development, neither uracil
1450 nucleotides nor CysLTs are suitable to this pur-
1451 pose, because neither ligand class is competent to
1452 discriminate between the functions of purinergic
1453 receptors, CysLT receptors, and GPR17 in vivo,
1454 where multiple receptors are often co-expressed.
1455 Nevertheless, the already available in vivo rodent
1456 data reporting positive neuro-reparative effects
1457 induced by commercially available montelukast
1458 or pranlukast (Yu et al. 2005a, b), which are
1459 potent (although non selective) GPR17
1460 antagonists, foster the search for further GPR17
1461 ligands (Eberini et al. 2011; Hennen et al. 2013)
1462 and may represent an important advancement for
1463 patients with neurodegenerative diseases.
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